Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
RadNetFRA:PQIA +2.55%78 EV-to-EBITDA is 23.14 as of Aug. 21, 2026, which is 126% above its 10-year median of 10.24. GuruFocus rates FRA:PQIA with a GF Score™ of 78/100 and a GF Value™ of €57.84 (Modestly Overvalued). The stock has 7 warning signs investors should review. Among 117 Medical Diagnostics & Research companies, RadNet ranks worse than 66.67% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, RadNet's enterprise value is €6,697 Mil.
RadNet's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was €289 Mil. Therefore, RadNet's EV-to-EBITDA for today is 23.14.
The historical rank and industry rank for RadNet's EV-to-EBITDA or its related term are showing as below:
FRA:PQIA'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 7.1 Med: 10.24 Max: 25.5
Current: 23.18
During the past 13 years, the highest EV-to-EBITDA of RadNet was 25.50. The lowest was 7.10. And the median was 10.24.
FRA:PQIA's EV-to-EBITDA is ranked worse than 66.67% of 117
companies
in the Medical Diagnostics & Research industry
Industry Median: 17.13
vs FRA:PQIA: 23.18
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2026-08-21), RadNet's stock price is €64.24.
RadNet's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 was €-0.234. Therefore, RadNet's PE Ratio (TTM) for today is At Loss.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
RadNet's share price for today is €64.24.
RadNet's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.234.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for RadNet's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:PQIA vs SHC, VCYT, TWST: EV-to-EBITDA Comparison
For the Diagnostics & Research subindustry, RadNet's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
RadNet EV-to-EBITDA vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, RadNet's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where RadNet's EV-to-EBITDA falls into.
RadNet's current Enterprise Value is €6,697 Mil.
RadNet's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €289 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RadNet (FRA:PQIA) has a EV-to-EBITDA of 23.14 as of Aug. 21, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on RadNet. This is 126% above median its historical median of 10.24. Over the past decade, RadNet's EV-to-EBITDA has ranged from 7.10 to 25.50. According to the industry distribution chart, RadNet ranks #78 out of 117 companies in the Medical Diagnostics & Research industry, placing it in the top 66.7%.
Is RadNet's EV-to-EBITDA too high?
RadNet's current EV-to-EBITDA of 23.14 is 126% above median its 10-year median of 10.24. Over the past 10 years, this metric has ranged from a low of 7.10 to a high of 25.50. The Medical Diagnostics & Research industry median EV-to-EBITDA is 17.13. RadNet's value of 23.14 is 35.1% above this industry median. Based on the distribution chart, RadNet ranks #78 out of 117 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, RadNet has a GF Score™ of 78/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does RadNet's EV-to-EBITDA compare to SHC and VCYT?
According to the Medical Diagnostics & Research industry distribution chart, RadNet ranks #78 out of 117 companies for EV-to-EBITDA. This places RadNet in the lower half of its industry. The industry median EV-to-EBITDA is 17.13. RadNet's value of 23.14 is 35.1% above this benchmark. Historically, RadNet's own EV-to-EBITDA has ranged from 7.10 to 25.50 over the past decade. While the company's 10-year median is 10.24 vs. the industry median of 17.13, RadNet has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Diagnostics & Research company?
The median EV-to-EBITDA among Medical Diagnostics & Research companies is 17.13, based on 117 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. RadNet's current EV-to-EBITDA of 23.14 is 35.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on RadNet. For the Medical Diagnostics & Research industry, the median EV-to-EBITDA is 17.13 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. RadNet's current EV-to-EBITDA is 23.14, which is 126% above median its own 10-year median of 10.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RadNet stock overvalued right now?
Based on GuruFocus' analysis, RadNet (FRA:PQIA) is currently considered Modestly Overvalued. The stock's GF Value™ is €57.84, compared to a current price of €64.24 — trading 11.1% above its estimated fair value. The current EV-to-EBITDA is 23.14, which is 126% above median its 10-year median of 10.24 and 35.1% above the Medical Diagnostics & Research industry median of 17.13. RadNet's overall GF Score™ is 78/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For RadNet (FRA:PQIA), the current EV-to-EBITDA is 23.14 as of Aug. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is RadNet (FRA:PQIA) Overvalued in 2026?
Based on GuruFocus' analysis, RadNet stock appears to be overvalued.
The current stock price of €64.24 is trading 11.1% above its estimated GF Value™ of €57.84.
GuruFocus considers RadNet to be Modestly Overvalued.
Key valuation signals for FRA:PQIA:
EV-to-EBITDA: 23.14 (126% above median its 10-year median of 10.24)
GF Value™: €57.84 vs. price of €64.24 (11.1% above fair value)
Industry Position: 35.1% above the Medical Diagnostics & Research median (#78 of 117)
No single metric tells the full story. See the FRA:PQIA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
RadNet Inc is a national provider of diagnostic imaging services that operates in two business segments: Imaging Center segment and Digital Health segment. The Imaging Center segment provides physicians with imaging capabilities to facilitate the diagnosis and treatment of diseases and disorders. Services include magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), nuclear medicine, mammography, ultrasound, diagnostic radiology (X-ray), and fluoroscopy. The Digital Health segment develops and deploys clinical applications to enhance the interpretation of medical images and improve patient outcomes with an emphasis on brain, breast, prostate, and pulmonary diagnostic.
78GF Score
Get the complete analysis for FRA:PQIA
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:PQIA has been successfully added to your 
